RxDoctor Payments Data

Marissa Rocourt, MD

Internal Medicine · Melbourne, FLNPI 1689758690

Payments from drug & device makers

$980in general payments, 2019–2025

Across 48 payments — averaging $20.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Astellas Pharma US Inc$375
  • Novo Nordisk$254
  • AbbVie$81
  • Lilly USA, LLC$40
  • Phathom Pharmaceuticals, Inc.$27
  • GSK$25
  • plus $177 from 11 others

What the payments were for

  • Food & beverage$69971%
  • Education$28129%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$980 in reported general payments places this provider in the 65th percentile of 8,530 internal medicine providers in Florida.

See all internal medicine providers in Florida

Medicare billing

Part B allowed, 2024
$153,254
Medicare patients
448
Services billed
1,685

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide167$204,625
MounjaroTirzepatide91$113,252
JardianceEmpagliflozin104$99,915
XareltoRivaroxaban70$77,338
EliquisApixaban72$71,516
FarxigaDapagliflozin Propanediol70$52,931
ProliaDenosumab28$45,273
Trelegy ElliptaFluticasone/Umeclidin/Vilanter25$30,603
TrulicityDulaglutide17$27,835
CreonLipase/Protease/Amylase12$26,733
Repatha SyringeEvolocumab33$26,240
MyrbetriqMirabegron34$25,036
Repatha SureclickEvolocumab11$13,994
GemtesaVibegron15$13,547
JanuviaSitagliptin Phosphate25$13,531

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$254$204,625167 claims
Lilly USA, LLCMounjaro, Trulicity$40$141,087108 claims
Boehringer IngelheimJardiance, Tradjenta$15$113,043123 claims
PfizerEliquis, Prempro, Premarin$18$80,724101 claims
Johnson & JohnsonXarelto$13$77,33870 claims
AstraZenecaFarxiga$17$52,93170 claims
GSKTrelegy Ellipta, Breo Ellipta$25$38,65541 claims
AbbVieCreon, Synthroid$81$36,870141 claims
Astellas Pharma US IncMyrbetriq$375$25,03634 claims
Sumitomo Pharma America, Inc.Gemtesa$17$13,54715 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$15$8,946556 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 8,530 internal medicine providers in Florida.

Other internal medicine in Melbourne

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →